Currently, the primary therapeutic strategy for most growth hormone-producing pituitary adenomas （GHPA） is surgery. Due to the invasiveness of GHPA, high recurrence has limited the benefit of complete adenoma remova...Currently, the primary therapeutic strategy for most growth hormone-producing pituitary adenomas （GHPA） is surgery. Due to the invasiveness of GHPA, high recurrence has limited the benefit of complete adenoma removal surgery. Epidermal growth factor-like domain 7 （EGFL7） is a secreted factor implicated in tumor angiogenesis, growth, invasiveness and metastasis in GHPA. Herein, we observed that the expression level of EGFL7 and p-EGFR in invasive GHPA was much higher than that ofnon-invasive GHPA. The overexpression of EGFL7 was positively correlated with activation of EGFR （p-EGFR）. Noticeably, EGFL7 knockdown sig- nificantly inhibited activation of EGFR signaling cascades, including p-ERGR, p-AKT and p-ERK. Further studies showed that EGFL7 knockdown or pharmacological inhibition of EGFR-pathway, using EGFR inhibitor Tyrphostin AG-1478, significantly suppressed migration and invasion of GH3 and GTI-1 cells. In summary, our findings suggest that EGFL7 is a key factor for regulation of EGFR signaling pathway and plays an important role in migration and invasion of invasive GHPA.展开更多
基金supported by the National Natural Science Foundation of China (81502154)Research Special Fund For Public Welfare Industry of Health of China (201402008)National High Technology Research and Development Program of China (2015AA020504)
文摘Currently, the primary therapeutic strategy for most growth hormone-producing pituitary adenomas （GHPA） is surgery. Due to the invasiveness of GHPA, high recurrence has limited the benefit of complete adenoma removal surgery. Epidermal growth factor-like domain 7 （EGFL7） is a secreted factor implicated in tumor angiogenesis, growth, invasiveness and metastasis in GHPA. Herein, we observed that the expression level of EGFL7 and p-EGFR in invasive GHPA was much higher than that ofnon-invasive GHPA. The overexpression of EGFL7 was positively correlated with activation of EGFR （p-EGFR）. Noticeably, EGFL7 knockdown sig- nificantly inhibited activation of EGFR signaling cascades, including p-ERGR, p-AKT and p-ERK. Further studies showed that EGFL7 knockdown or pharmacological inhibition of EGFR-pathway, using EGFR inhibitor Tyrphostin AG-1478, significantly suppressed migration and invasion of GH3 and GTI-1 cells. In summary, our findings suggest that EGFL7 is a key factor for regulation of EGFR signaling pathway and plays an important role in migration and invasion of invasive GHPA.
